Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase I/II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Ofranergene obadenovec (Primary) ; Bevacizumab
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Sponsors VBL Therapeutics
- 18 Dec 2017 According to a VBL Therapeutics media release, results from this trial were presented at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO),
- 14 Aug 2017 According to a VBL Therapeutics media release,the company provided an update on long-term survival for the phase 2 part from this trial at the BIO International Convention.
- 19 Jun 2017 According to a VBL Therapeutics media release, long-term survival data from this trial will be presented at 2017 BIO International Convention.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History